Endogenous B-type natriuretic peptide: a limb of the regulatory response to acutely decompensated heart failure.
Acutely decompensated heart failure (ADHF) represents an episodic failure of cardiorenal homeostasis that may resolve with upregulation of natriuretic peptides, bradykinin, and certain prostacyclins. B-type natriuretic peptide (BNP) has multiple favorable effects, including vasodilation, diuresis, natriuresis, and inhibition of vascular endothelial proliferation and cardiac fibrosis. By antagonizing the effects of activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system in volume overload, the endogenous BNP response may help rescue patients from episodic ADHF. Although knowledge of BNP physiology is expanding, we still have limited understanding of the heterogeneity of proBNP-derived molecules, including active 32 amino acid BNP and less active junk BNP forms. Emerging evidence suggests that in ADHF, the endogenous BNP response is overwhelmed by neurohormonal activation. This relative BNP deficiency may also be accompanied by physiologic resistance to BNP. Additionally, abnormalities of BNP production may result in a lower proportion of active BNP relative to less active forms that may also be detected by point-of-care tests. Improved detection of the various BNP species may clarify these concepts and facilitate improved clinical management of ADHF.
Hobbs
Robert E
RE
Section of Heart Failure and Transplant Medicine, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. hobbsr@ccf.org
Mills
Roger M
RM
D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000503:physiopathology; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000502:physiology; D013564:Sympathetic Nervous System / Q000502:physiology
D020097:Natriuretic Peptide, Brain
Crit Pathw Cardiol. 2005 Mar;4(1):10-20
18340179
Clin Chem. 2004 Sep;50(9):1503-10
15265821
Rev Cardiovasc Med. 2003 Spring;4(2):72-80
12776016
J Card Fail. 2006 Feb;12(1):e1-2
16500560
Can J Physiol Pharmacol. 2001 Aug;79(8):730-5
11558682
Expert Opin Investig Drugs. 2001 May;10(5):935-42
11322867
Arq Bras Cardiol. 2005 Sep;85 Suppl 3:49-94; 1-48
16211166
Expert Opin Investig Drugs. 2004 Jun;13(6):643-52
15174950
Pharmacol Ther. 2004 Feb;101(2):113-29
14761702
Am Heart J. 2003 Feb;145(2 Suppl):S18-25
12594448
Clin Chim Acta. 2003 Aug;334(1-2):233-9
12867297
Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):406-16
10519161
Mt Sinai J Med. 2006 Mar;73(2):506-15
16568193
Life Sci. 1997;61(12):1185-92
9315509
Circ Res. 1994 Mar;74(3):471-6
8118955
N Engl J Med. 2002 Jul 18;347(3):161-7
12124404
Am Heart J. 2003 Feb;145(2 Suppl):S34-46
12594450
Eur Heart J. 2005 Feb;26(4):384-416
15681577
Circulation. 2003 Dec 16;108(24):2964-6
14662703
Am J Physiol. 1998 May;274(5):H1684-9
9612380
J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8
17349887
Trends Endocrinol Metab. 2003 Nov;14(9):411-6
14580760
Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R897-901
17068158
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17442-7
16293687
Clin Chim Acta. 2002 Feb;316(1-2):129-35
11750283
Circ Res. 2003 Oct 17;93(8):700-9
14563709
Curr Opin Nephrol Hypertens. 2006 Jan;15(1):14-21
16340661
Curr Cardiol Rep. 2000 May;2(3):198-205
10980893
Hypertension. 2007 May;49(5):1114-9
17372040
Fundam Clin Pharmacol. 2005 Aug;19(4):411-9
16011727
Pharmacotherapy. 2003 Aug;23(8):997-1020
12921247
J Am Coll Cardiol. 2007 Mar 13;49(10):1079-88
17349888
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4239-44
10737768
Am Heart J. 2005 Apr;149(4):744-50
15990762
Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):87-98
15853696
Clin Sci (Lond). 2005 Jan;108(1):23-36
15476436
Can J Physiol Pharmacol. 2001 Aug;79(8):705-14
11558679
Rev Cardiovasc Med. 2004;5 Suppl 4:S3-16
15627917
J Am Coll Cardiol. 2007 Mar 13;49(10):1089-91
17349889